Avalo Therapeutics Inc expected to post a loss of 80 cents a share - Earnings Preview

Avalo Therapeutics

31/07/2023 15:40

* Avalo Therapeutics Inc  AVTX.OQ   AVTX.O  is expected
to show a
fall in quarterly revenue when it reports  results on August 2
(estimated). 
    * The Rockville Maryland-based  company is expected to
report  a
51.6% decrease in revenue to $500 thousand from $1.03 million a
year ago, according to the mean estimate from 2 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Avalo Therapeutics
Inc is
for a loss of 80 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Avalo
Therapeutics Inc is $0.75​, above​ its last closing price
of $0.19. ​​​

This summary was machine generated July 31 at 14:40 GMT.  All
figures in US dollars  unless otherwise stated